BioSpace News Archive

Bio-Techne Corporation announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company’s Board of Directors, April 24, 2024.

ASLAN Pharmaceuticals announced that it will host a virtual Key Opinion Leader Event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, to be held on Tuesday, May 7, 2024 from 8:00 AM ET to 9:00 AM ET.

HanAll Biopharma achieved 18.4 percent revenue growth in the first quarter compared to the same period last year, recording a revenue of 34.1 billion Korean Won, driven by continued strong sales across key products.

Oncolytics Biotech ® Inc. today announced that it will host a conference call and webcast on Thursday, May 9, 2024.

Harmony Biosciences, announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM designation by the US Food and Drug Administration.

Emmetrope Ophthalmics LLC, a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, announced final dose administration for the last patient in its U.S. randomized, double-masked, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

Enanta Pharmaceuticals, Inc. announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC clinical trial investigating lunresertib in combination with Debio 0123.